Campaigners welcomed a decision to approve a new weekly injection to treat those with severe haemophilia B for use by the NHS ...
A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual ...
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC37 injection, a next-generation, once-monthly, subcutaneously administered GLP-1R/GIPR/GCGR[1] triple peptide agonist, ...
Biogen and Eisai recently announced that Chinese regulators have accepted their Biologics License Application for a ...
Abbvie (ABBV) announced an update on their ongoing clinical study.
The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.
Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
Detailed price information for Schrodinger Inc (SDGR-Q) from The Globe and Mail including charting and trades.
VANCOUVER, BC / ACCESS Newswire / January 15, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce the launch of a ...
ZYCUBO is a subcutaneous injectable formulation of copper histidinate designed to restore copper homeostasis and maintain adequate copper levels in patients with Menkes disease.
Clinical Trials in Cancer Cachexia, Inflammatory Bowel Disease and Retinal Disorders are Planned MONTVALE, N. J., Jan. 07, 2026 (GLOBE ...
Health Canada has cleared the way for ALS patients in that nation to join the ongoing ALSTARS U.S. trial testing therapy candidate COYA 302.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback